Sep 2026
Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure
K. Tak, Hee Sun Cho, Jaejun Lee et al.
· Targeted oncology · 0 citations